Insulin degludec/insulin aspart
| Combination of | |
|---|---|
| Insulin degludec | Long-acting human insulin analog |
| Insulin aspart | Fast-acting human insulin analog |
| Clinical data | |
| Trade names | Ryzodeg |
| AHFS/Drugs.com | Professional Drug Facts |
| License data | |
| Pregnancy category | |
| Routes of administration | Subcutaneous injection |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Insulin degludec/insulin aspart, sold under the brand name Ryzodeg, is a fixed-dose combination medication for the treatment of diabetes mellitus.[3] It contains insulin degludec and insulin aspart.[3] It is given as an injection under the skin in the abdominal wall (at the front of the waist), upper arm or thigh.[3]
The most frequently reported side effect is hypoglycemia (low blood glucose levels).[3]
It was approved for medical use in the European Union in January 2013,[3] and in Australia in November 2017.[2]
Medical uses
Insulin degludec/insulin aspart is indicated for the treatment of diabetes mellitus in adults, adolescents and children from the age of two years.[3]
Insulin degludec and insulin aspart are slightly different from human insulin.[3] The differences mean that insulin degludec is absorbed more slowly by the body.[3] This means it has a long duration of action.[3] Meanwhile, insulin aspart is absorbed faster by the body than human insulin, and therefore it starts to work as soon as it is injected and has a short duration of action.[3]
References
- ↑ "Insulin aspart / insulin degludec (Ryzodeg 70/30) Use During Pregnancy". Drugs.com. 30 June 2020. Retrieved 26 July 2020.
- 1 2 3 "Ryzodeg 70/30 FlexTouch and Penfill (insulin degludec/insulin aspart) solution" (PDF). Novo Nordisk Pharmaceuticals Pty Ltd.
- 1 2 3 4 5 6 7 8 9 10 11 "Ryzodeg EPAR". European Medicines Agency (EMA). Retrieved 18 July 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
External links
- "Insulin aspart mixture with insulin degludec". Drug Information Portal. U.S. National Library of Medicine.
- Australian Public Assessment Report for insulin degludec (rys)/insulin aspart (rys) (PDF) (Report). Therapeutic Goods Administration (TGA).